Evidence map›Paper›PMID 28567600›Full record

ArticlePathology oncology research : POR2018

Dabrafenib Therapy in 30 Patients with Melanoma Metastatic to the Brain: a Single-centre Controlled Retrospective Study in Hungary.

Eszter Gorka, Dániel Fabó, András Gézsi, Kata Czirbesz, Imre Fedorcsák, Gabriella Liszkay

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.Current treatment options in oncology · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Eszter GorkaDermatooncology Department, National Institute of Oncology, Ráth György str. 7-9, Budapest, H-1122, Hungary. goreszter@yahoo.com.ORCID http://orcid.org/0000-0002-8146-045X
Dániel FabóEpilepsy Centrum, Department of Neurology, National Institute of Clinical Neurosciences, Amerikai str. 57, Budapest, H-1145, Hungary.
András GézsiDepartment of Genetics, Cell- and Immunbiology, Semmelweis University, Nagyvárad sq. 4, Budapest, H-1084, Hungary.
Kata CzirbeszDermatooncology Department, National Institute of Oncology, Ráth György str. 7-9, Budapest, H-1122, Hungary.
Imre FedorcsákEpilepsy Centrum, Department of Neurology, National Institute of Clinical Neurosciences, Amerikai str. 57, Budapest, H-1145, Hungary.
Gabriella LiszkayDermatooncology Department, National Institute of Oncology, Ráth György str. 7-9, Budapest, H-1122, Hungary.
National Institute of Oncology · HUOrszágos Idegsebészeti Tudományos Intézet · HUSemmelweis University · HU

Funding

Hungarian Government KTIA_NAP 13-1-2013-0001
6 · The paper itself

Abstract

Dabrafenib is a potent BRAF inhibitor, which showed intracranial tumor activity. The purpose of our retrospective analysis was to evaluate the efficacy of dabrafenib for patients with melanoma brain metastasis (BM). We studied 30 BRAF mutant melanoma patients with BM, who received dabrafenib after local control of the brain between 2014 and 2017. Eastern Cooperative Oncology Group Performance Status (ECOG) was 0-2. The control arm consisted of 204 melanoma patients from our institutional melanoma database with BM and ECOG 0-2 treated with local therapies and/or chemotherapy, between 2003 and 2015. We found the intracranial disease control rate (DCR) was 83% including four (13%) complete remissions (CR), nine (30%) partial remissions (PR) and twelve (40%) stable diseases (SD) in contrast to five (17%) progressive diseases (PD). With a median follow-up of 14 months, median progression-free survival (PFS) and overall survival (OS) were 5.5 months, and 8.8 months, respectively. If calculated from BM onset, the OS turned to be 11.8 months on the dabrafenib arm, while it was only 6.0 months in the control arm (HR = 0.45, p = 0.0014). Higher risk of progression was observed with increasing ECOG (HR =4.06, p = 0.00027) and if more than 2 extracranial organs were involved (HR = 3.4, p = 0.0077). Elevated lactate dehydrogenase (LDH) was non-significantly associated with worse clinical outcome. Remarkable intracranial activity of dabrafenib in real practice was confirmed by our analysis.

Indexed as

AdultAgedAntineoplastic AgentsBrain NeoplasmsDisease-Free SurvivalFemaleHumansHungaryImidazolesMaleMelanomaMiddle AgedOximesRetrospective StudiesTreatment OutcomeYoung AdultAntineoplastic AgentsdabrafenibImidazolesOximesBRAFBrain metastasesDabrafenibMelanomaTargeted therapy

Identifiers

PMID28567600
OpenAlexW2619970401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.